Priovant Therapeutics announced positive Phase 2 NEPTUNE study results for brepocitinib in Non-Infectious Uveitis (NIU), showing strongest efficacy data in NIU observed to date. Brepocitinib selectively binds to and inhibits the activation of TYK2 and JAK1, thereby disrupting TYK2 and JAK-1-dependent cytokine signaling. This may reduce inflammatory responses and prevent inflammation-induced damage caused by certain immunological diseases.
Search 
+86 21 5895 0110 
![tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate](https://images.chemenu.com/attachments/products_new/svg/149771-44-8.svg)
